BILAG Biologics Register

 Lupus / Posted 2 years ago

The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE).  (Long-term Safety of New Treatments in the Management of SLE)

The BILAG Biologics Register (BILAG BR) is a study underway at hospitals throughout the UK.
It is looking at the safety and effectiveness of biologic and biosimilar treatment for systemic lupus erythematosus (SLE).

Biologic drugs use substances that are made from living organisms, and use the body’s natural immune system to treat a disease.

This can be done by stimulating or suppressing part of the immune system to help the body fight the disease.

We’ll follow your progress through your hospital care team, who will collect data on your lupus symptoms and treatment when you attend your routine hospital appointments.

With your consent, we will collect urine samples from you, as well as extra blood samples at the same time as your usual blood tests, so you will not need to have any extra trips to the hospital.

We will also ask you to fill in some questionnaires about your lupus symptoms and how they affect your life.

We will send you the same questionnaires at regular intervals throughout the study; initially three and six months after your treatment, and then annually.

You will also be asked to keep a diary of changes in medication, hospital stays and appointments. We would like to collect this information for at least five years, but longer if possible.

By participating in the study, you will be contributing towards the amount of data available for researchers to look at the safety and effectiveness of biologic treatments for lupus.

If you are not involved in the study but would like to be, please speak with your hospital care team to see if you are eligible to join.

  • Inclusion Criteria :
    • Diagnosis of Systemic Lupus Erythematosus (SLE).
    • Aged five years or older.
  • Exclusion Criteria :
    • None Specified
  • Study start date : 01/09/2010
  • Study end date : 28/02/2021
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Dr Ceril Rhys Dillon

No post found